Of note, many of the above described mechanisms are acquired during treatment but little is known about primary resistance, which is a highly relevant clinical issue, since nearly 40% of patients with BRCA1/2-associated breast cancer patient have no detectable response when receiving PARP inhibitors. This evidence concerns the gene PARP1 and breast carcinoma.